Curevac says speaking to EU about ideal region to use vaccine

FRANKFURT: Curevac said it was in discussions with its prospective customer, the European Union, about where in the world to best deploy its experimental COVID-19 vaccine if it wins approval.

Under Curevac's only major supply deal, the European Union last year secured up to 405 million doses of the vaccine in November, of which 180 million doses were optional. Curevac said on Thursday it was in ongoing discussions with the region's drugs regulator, the European Medicines Agency (EMA), about an approval.